Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of lapatinib in treating patients who have
recurrent and/or metastatic adenoid cystic cancer or other salivary gland cancers. Lapatinib
may stop the growth of tumor cells by blocking the enzymes necessary for their growth.